Magnolia Medical

Magnolia Medical

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.magnolia-medical.com

Last Round

Series D

Feb 16, 2022

Total Funding Raised

$87.05M

Momentum Score

25 /100

Company Overview

Magnolia Medical Technologies is a healthcare company that offers a blood-collection system aimed at preventing sepsis misdiagnosis by eliminating false-positive blood culture results through a sterile, closed collection process that ensures accurate diagnostics and improved patient outcomes.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Healthcare Analytics, Quality Management

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts, Services & Consulting, Data as a Service, Hardware + Subscription

AI Layer

Non-AI

Keywords

blood culture contaminationinitial specimen diversionSteripathsepsis misdiagnosisspecimen diversion deviceISDDantibiotic stewardshipblood collection deviceFDA 510(k) clearancefalse positive reductionphlebotomy deviceFDA cleared devicehealthcare analyticshospital suppliesclinical implementationB2G medical sales

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Magnolia Medical Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Magnolia Medical Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series DFeb 16, 2022
Series CJan 30, 2019
Series B ExtensionApr 4, 2017
Series BJul 13, 2016

Key People

Founding team and executive leadership

Jason Richey

President Chief Executive Officer

Executive Team

Joe Bishop

Chief Operating Officer

Executive Team

Magnolia Medical Investors

Notable investors and investment history

InvestorRounds
Janus Henderson GroupSeries D
Evidity Health CapitalSeries D
SightLine PartnersSeries D, Series C
SectoralSeries D
RTW InvestmentsSeries C
Canepa HealthcareSeries C, Series B Extension
HealthQuest CapitalSeries D, Series C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Company holds over 70 issued patents with 50+ applications pending.

  • Apr 1, 2026

    Steripath device receives FDA-cleared indication for reducing blood culture contamination.

Magnolia Medical Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Magnolia Medical Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Magnolia Medical's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range83
Year Founded2006
Last FundingFeb 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.